Guardian Pharmacy (NYSE: GRDN) reiterates 2025 outlook, gives 2026 view

Rhea-AI Filing Summary

Guardian Pharmacy Services, Inc. reiterated its previously issued financial guidance for the full year ended December 31, 2025 and shared an early financial outlook for 2026. These updates were released through a press release that is furnished as an exhibit.

The company also prepared an investor presentation about its business for use at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at approximately 4:30 p.m. Pacific Time, as well as in meetings with investors, analysts, and other interested parties. Both the press release and the presentation are provided as supplemental materials to inform the market about current expectations and business positioning.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001802255 0001802255 2026-01-13 2026-01-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2026

Guardian Pharmacy Services, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42284		87-3627139
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

300 Galleria Parkway SE
Suite 800
Atlanta, Georgia		30339
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (404) 810-0089

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.001 per share		GRDN		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 13, 2026, Guardian Pharmacy Services, Inc. (the “Company”) issued a press release reiterating the Company’s previously issued financial guidance for the full year ended December 31, 2025 and providing the Company’s preliminary financial outlook for 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

The Company has prepared a presentation concerning its business that it intends to use in connection with the Company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at approximately 4:30 p.m. Pacific Time and for meetings with investors, analysts, and other interested parties. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth in this Item 7.01 (including Exhibit 99.2) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 13, 2026.
99.2		Company Presentation, dated January 13, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Guardian Pharmacy Services, Inc.
January 13, 2026				By:		/s/ David K. Morris
				Name:		David K. Morris
				Title:		Executive Vice President and Chief Financial Officer

FAQ

What did Guardian Pharmacy Services, Inc. (GRDN) announce in this report?

Guardian Pharmacy Services, Inc. reiterated its previously issued financial guidance for the full year ended December 31, 2025 and provided a preliminary financial outlook for 2026 through a furnished press release.

How is Guardian Pharmacy Services, Inc. (GRDN) communicating its 2025 and 2026 expectations?

The company is communicating its expectations via a press release that reiterates full-year 2025 financial guidance and outlines a preliminary 2026 outlook, which is furnished as Exhibit 99.1.

What investor materials did Guardian Pharmacy Services, Inc. (GRDN) provide?

Guardian Pharmacy Services, Inc. furnished a press release as Exhibit 99.1 and a company presentation as Exhibit 99.2, both dated January 13, 2026.

Why is Guardian Pharmacy Services, Inc. (GRDN) presenting at the J.P. Morgan Healthcare Conference?

The company prepared a business presentation for its appearance at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 and for meetings with investors, analysts, and other interested parties.

Are the Guardian Pharmacy Services, Inc. (GRDN) exhibits considered filed with the SEC?

The press release and the company presentation are furnished, not deemed filed for purposes of certain Exchange Act and Securities Act provisions, except where specifically incorporated by reference.

What exhibits are included with this Guardian Pharmacy Services, Inc. (GRDN) report?

The report includes Exhibit 99.1 (press release dated January 13, 2026), Exhibit 99.2 (company presentation dated January 13, 2026), and Exhibit 104 (cover page interactive data file).